Background and objectives Data from observational and interventional studies provide discordant results regarding the relationship between creatinine increase after renin-angiotensin system inhibition (RASi) and adverse outcomes. We compared health outcomes among patients with different categories of increase in creatinine upon initiation of RASi in a large population-based cohort. Design, setting, participants, & measurements We performed a retrospective analysis of the Stockholm CREAtinine Measurements database, which contains complete information on diagnoses, medication dispensation claims, and laboratory test results for all Stockholm citizens accessing health care. Included were 31,951 adults initiating RASi during 2007–2011 with available pre- and postinitiation creatinine monitoring. Multivariable Cox regression was used to compare mortality, cardiovascular and ESKD events among individuals with different ranges of creatinine increases within 2 months after starting treatment. Results In a median follow-up of 3.5 years, acute increases in creatinine were associated with mortality (3202 events) in a graded manner: compared with creatinine increases <10%, a 10%–19% increase
Archivi categoria: malattie renali
Association of Acute Increases in Plasma Creatinine after Renin-Angiotensin Blockade with Subsequent Outcomes | American Society of Nephrology
Are There Fast-Food Choices for End-Stage Renal Disease Patients? A Look at Phosphorus and Potassium Content in Common Fast Foods – Journal of Renal Nutrition
Fast food is cheap, convenient, and common for the average American; adults consume an average of 11.3% of their daily calories from fast food.1 Fast food has become routine in most American’s lifestyles, including people with end-stage renal disease (ESRD). It is known that most fast foods are high in calories, fat, sugar, and salt because fast-food companies must provide nutritional facts at their stores and online.2 The phosphorus and potassium concentrations in foods are unfortunately not readily available to most patients or practitioners.
The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach – American Journal of Kidney Diseases
Erythropoiesis-stimulating agents (ESAs) have been used to manage anemia in chronic kidney disease (CKD) to reduce transfusion requirements and anemia symptoms. Lack of objective benefit of normalizing hemoglobin (Hb) levels and increased evidence of ESA-induced complications in persons with anemia has resulted in clinicians generally attempting to maintain Hb levels in the 10- to 11-g/dL range. In 2000, concerns in patients with cancer arose attributable to associations of ESA use with increased mortality, thrombotic complications, and cerebrovascular accidents led to a change in US Food and Drug Administration oncology guidelines regarding limitation of ESA use for chemotherapy-induced anemia.
Decision Aids for Prostate Cancer Screening Choice: A Systematic Review and Meta-analysis | Cancer Screening, Prevention, Control | JAMA Internal Medicine | JAMA Network
This systematic review and meta-analysis of 19 randomized clinical trials estimates the association of decision aids with decisional outcomes in prostate cancer screening.
Management of hyperkalemia in patients with kidney disease: a position paper endorsed by the Italian Society of Nephrology. – PubMed – NCBI
PubMed comprises more than 29 million citations for biomedical literature from MEDLINE, life science journals, and online books. Citations may include links to full-text content from PubMed Central and publisher web sites.